PR
EWTX icon

PSP Research’s Edgewise Therapeutics EWTX Stock Holding History

PSP Research’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Sell
5,000
-1,500
-23% -$51.7K 0.11% 69
2026
Q1 		$205K Buy
+6,500
New +$187K 0.14% 72

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's EWTX Position: Q2 2026 in Review

PSP Research reduced its Edgewise Therapeutics (EWTX) stake by 23% in Q2 2026, selling an estimated $51.7K and leaving 5,000 shares worth $203K. The position accounts for 0.11% of the portfolio, ranked #69.

PSP Research first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $205K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • PSP Research held 5,000 shares of Edgewise Therapeutics worth $203K as of Q2 2026.
  • PSP Research sold 1,500 Edgewise Therapeutics shares in Q2 2026, an estimated $51.7K.
  • Edgewise Therapeutics made up 0.11% of PSP Research's portfolio in Q2 2026, its #69 holding.
  • PSP Research first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • PSP Research's Edgewise Therapeutics position peaked at $205K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.